Review

Introduction

Combination vaccines allow the administration of antigens that target multiple diseases in a single injection. The potential benefits of combination vaccines over separate administration of the component parts include increased patient and health care professional acceptance of the administration of multiple antigens at one visit; lower vaccination costs as a result of fewer required office visits; greatly reduced storage requirements for vaccines as well as reduced risk of administration errors and of missed doses.

Studies from the United States\textsuperscript{1-3} and Germany\textsuperscript{4} show that the use of combination vaccines is associated with improved coverage of individual antigens and with more timely vaccination: this means that a higher percentage of children receive all their recommended vaccines at the recommended age.

Hexavalent vaccines targeting six diseases are the largest multi-component combination vaccines currently available. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been associated with record levels of vaccine coverage, and with sustained disease control in vaccinated cohorts. Hexavalent vaccines will continue to contribute to high vaccine coverage in Italy and across Europe.

Keywords: hexavalent vaccine, primary vaccination, booster vaccination, Italy, combination vaccines, immunogenicity, safety

Abbreviations: μg/ml, micrograms per milliliter; ATP, according to protocol; CI, confidence interval; DTPa-HBV-IPV/Hib, diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus and \textit{Haemophilus influenzae} type b vaccine; ELISA, enzyme-linked immunosorbent assay; EL.U/ml, ELISA units per milliliter; FHA, filamentous haemagglutinin; GMC, geometric mean antibody concentration; IU/ml, international units per milliliter; mIU/ml, milli-international units per milliliter; PRN, pertactin; PRP, polyribosylribitol phosphate; PT, pertussis toxoid; SP, seroprotection; S+, seropositivity; VR, vaccine response; WHO, World Health Organization

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been associated with record levels of vaccine coverage, and with sustained disease control in vaccinated cohorts. Hexavalent vaccines will continue to contribute to high vaccine coverage in Italy and across Europe.
DTPa-HBV-IPV/Hib is one of few acellular pertussis vaccines that contain PRN, which appears to be important in protection against pertussis disease. PRN is a *Bordetella pertussis* surface protein thought to promote adhesion and colonization of the respiratory tract. While all pertussis vaccines contain PT and many contain FHA (so-called 1- or 2-component pertussis vaccines), not all contain PRN (3-, 4-, or 5-component vaccines).

DTPa-HBV-IPV/Hib is indicated for primary and booster vaccination of infants and toddlers, and has been studied in a range of commonly used vaccination schedules. Data have been generated in children between 6 weeks of age and less than 36 mo. Much of the clinical data during the development of DTPa-HBV-IPV/Hib were obtained in studies that employed a 3-dose primary vaccination schedule with a booster in the second year of life. However, administration in a 2-dose primary vaccination at 3 and 5 mo of age, with a booster administered at 11–12 mo of age (3-5-11 schedule) is also specifically approved in the Summary of Product Characteristics.

The magnitude of the immune response to some antigens may be lower after two priming doses than after three doses, the percentage of subjects achieving seroprotection/seropositivity for each of the vaccine antigens is similar: ranging between 91.7 and 100% after 2 doses and between 96.4 and 100% after 3 doses. Similarly, seroprotection/seropositivity rates are comparable after the booster dose in infants primed with 2 or 3 vaccine doses (range 99.2 to 100% and 98.4 to 100%, respectively). The 3-5-11 schedule decreases the cost and complexity of the immunisation schedule, and promotes high rates of immunization coverage. The 3-5-11 schedule was pioneered in Italy in the 1970s, and is now also used in Austria, Denmark, Finland, Iceland, Norway, France, and Sweden, and is being considered in Poland and other countries. The 3-5-11 schedule is used in regions where infectious pressure is low and where high uptake of the booster dose is achieved. Alternative 3-dose primary schedules beginning earlier in life with/without neonatal hepatitis B vaccination are used in countries where infectious pressure is high, and where there is a higher risk of exposure to disease early in life.

DTPa-HBV-IPV/Hib has been available for use in Italy since 2001. The introduction of hexavalent vaccines to Italy was followed by increases in vaccine coverage rates, with coverage of 3 doses of Hib vaccine increasing from 54.7% in 2000 to 83.4% in 2002, and coverage of 3 doses of pertussis vaccine increasing from 87.3% in 2000 to 92.9% in 2002. By 2011, vaccine coverage for three doses of DTPa, poliovirus, hepatitis B, and Hib in Italy was more than 95%.

This review summarizes the available immunogenicity, reactivity, safety, and effectiveness data after 12 y of experience using DTPa-HBV-IPV/Hib, focusing on the 3-5-11 schedule in the Italian context.

### Clinical Studies that Evaluated DTPa-HBV-IPV/Hib Administered to Infants at 3, 5, and 11 Mo of Age

We identified seven clinical trials that evaluated the immunogenicity and/or safety of DTPa-HBV-IPV/Hib administered...
to infants according to the 3-5-11 schedule (Table 1).13-17,19,20 In three of the studies DTPa-HBV-IPV/Hib was co-administered with another vaccine: either meningococcal serogroup C conjugate vaccine (MenC-TT) or a pneumococcal conjugate vaccine (PCV).

**Immunogenicity and Efficacy**

Well-established serological correlates of protection exist for antibodies against tetanus, diphtheria, hepatitis B, polio, and Hib. Therefore, for these antigens, efficacy of DTPa-HBV-IPV/Hib in preventing disease is extrapolated from the percentage of subjects who reach serological thresholds accepted as correlates of protection. The exception to this is pertussis, for which no correlate of protection currently exists.

**Diphtheria and tetanus**

In each study, antibodies against diphtheria and tetanus were measured by enzyme-linked immunosorbant assay (ELISA), with the assay cut-off of 0.1 IU/ml which is at least 10 times the generally accepted threshold for seroprotection.21,22 In groups that received DTPa-HBV-IPV/Hib, the percentage of subjects that achieved seroprotective (≥0.1 IU/ml) antibody concentrations after the second primary vaccination dose was between 92.8% and 100% for diphtheria and between 92.5% and 100% for tetanus (Table 2). After the booster dose, the percentage increased to 100% for diphtheria and was 100% for tetanus in all studies except when co-administered with 7-valent PCV (PCV7) (93.8%) or 13-valent PCV (PCV13) (97.6).19 Of note, in a field study in Italy in which DTPa-HBV-IPV/Hib was co-administered with PCV7, the anti-tetanus seroprotection rate after the booster dose was 100%,20 suggesting that co-administration with PCV7 was not responsible for the somewhat lower seroprotection rates observed by Esposito et al.19

**Pertussis**

Antibodies against PT, FHA, PRN were measured by ELISA,23,24 with an assay cut-off of 5 EL.U/ml. In studies

---

**Table 2. Seroprotection/seropositivity rates at each blood sampling time point (ATP immunogenicity cohorts*)**

| Study   | Group                  | D %SP | T %SP | PT %S+ | FHA %S+ | PRN %S+ | HBs %SP | Polio-1 %SP | Polio-2 %SP | Polio-3 %SP | Hib %SP |
|---------|------------------------|-------|-------|--------|---------|---------|---------|-------------|-------------|-------------|---------|
| 031     | DTPa-HBV-IPV/Hib       | Post 2| 100   | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 99.3    |
|         |                        | Pre 3 | 86.4  | 96.4   | 95.7    | 100     | 86.4    | 95.7        | 94.4        | 91.9        | 80.3    |
|         |                        | Post 3| 100   | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 99.2    |
| 054     | DTPa-HBV-IPV/Hib       | Post 2| 97.1  | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 99.4    |
|         |                        | Pre 3 | 84.0  | 94.4   | 98.1    | 100     | 95.5    | 96.1        | 89.3        | 84.5        | 95.3    |
|         |                        | Post 3| 100   | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 93.7    |
| 060     | DTPa-HBV-IPV/Hib       | Post 2| 96.2  | 100    | 97.5    | 98.7    | 96.1    | 98.2        | 100         | 97.1        | 94.3    |
|         |                        | Pre 3 | NT    | NT     | NT      | NT      | NT      | NT          | NT          | NT          | 89.9    |
|         |                        | Post 3| 100   | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 100     |
| 094     | DTPa-HBV-IPV/Hib       | Post 2| NT    | NT     | NT      | NT      | NT      | NT          | NT          | NT          | NT      |
|         |                        | Pre 3 | 71.0  | 92.4   | 84.2    | 99.1    | 91.0    | 89.7        | NT          | NT          | 79.5    |
|         |                        | Post 3| 100   | 100    | 100     | 100     | 98.6    | 99.1        | 95.5        | 98.5        | 97.9    |
| 014/015 | DTPa-HBV-IPV/Hib + MenC-TT | Post 2| NT    | NT     | NT      | NT      | NT      | NT          | NT          | NT          | NT      |
|         |                        | Pre 3 | NT    | NT     | NT      | NT      | NT      | NT          | NT          | NT          | NT      |
|         |                        | Post 3| NT    | NT     | NT      | NT      | NT      | NT          | NT          | NT          | NT      |
| Esposito| DTPa-HBV-IPV/Hib + PCV13| Post 2| 92.8  | 94.2   | 99.6    | 100     | 100     | 93.8        | 99.5        | 95.6        | 99.5    |
|         |                        | Pre 3 | 100   | 97.6   | 100     | 100     | 100     | 98.4        | 100         | 100         | 100     |
|         |                        | Post 3| 100   | 93.8   | 100     | 100     | 100     | 98.8        | 100         | 100         | 98.2    |
| Durando | DTPa-HBV-IPV/Hib       | Post 3| NT    | NT     | NT      | NT      | NT      | NT          | NT          | NT          | NT      |
|         |                        | Post 3| 100   | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 100     |
|         |                        | Post 3| 100   | 100    | 100     | 100     | 100     | 100         | 100         | 100         | 100     |

N, number of subjects in ATP cohorts for immunogenicity (total vaccinated cohort for study 060). For Study 094, post-dose-2 blood samples were collected by only 2 centers for testing of anti-PRP and anti-HBs antibodies. NT, blood samples not taken at this time point in the indicated study. SP, seroprotection. For D and T ≥ 0.1 IU/ml, HBs ≥ 10 miU/ml, poliovirus types 1, 2, 3 ≥1:8, Hib ≥ 0.15 μg/ml. S+, seropositivity, for PT, FHA, and PRN ≥ 5 EL.U/ml. *Analysis on the Total vaccinated cohort for study DTPa-HBV-IPV-060.
conducted using the 3-5-11 mo schedule, at least 93.1% of subjects were seropositive for antibodies for PT, FHA, or PRN after dose 2 (Table 2). After the booster dose, 100% of subjects were seropositive for PT and FHA and at least 98.6% were seropositive for PRN.

No serological correlate of protection against pertussis disease is currently generally accepted. However, efficacy of GlaxoSmithKline Vaccines’ pediatric pertussis vaccine (DTPa, Infanrix™) was demonstrated in a German household contact study in the 1990s. Efficacy against World Health Organization-defined typical pertussis after 3-dose primary vaccination was 88.7% (95% confidence interval [CI]: 76.6%; 94.6%).25,26 Efficacy was also confirmed in a large placebo-controlled prospective cohort study conducted in Italy under the auspices of the United States National Institute of Allergy and Infectious Diseases (Progetto Perotose). In the Italian setting, efficacy against WHO-defined pertussis after 3-dose primary vaccination was 83.9% (95% CI: 75.8%; 89.4%).27 Follow-up of subjects for up to 60 mo after vaccination showed no decrease in vaccine efficacy over this period, even though a booster dose was not administered in the second year of life.28 The pertussis component of DTPa-HBV-IPV/Hib is identical to that of DTPa, and protection against pertussis disease is therefore likely to be of similar magnitude and duration following primary vaccination with either DTPa-HBV-IPV/Hib or DTPa.

Sweden re-introduced pertussis vaccination in 1996 after a 17-y pertussis-vaccine free period, with doses of DTPa administered at 3, 5, and 11 mo of age. Post-marketing data from Sweden attest to the effectiveness of the 3-5-11 schedule, with marked reductions in pertussis disease incidence rates observed in vaccinated cohorts.29,30 The highest incidences of pertussis disease in settings of high vaccine coverage such Sweden,29 Italy,31 as well as countries that use 3-dose primary vaccination schedules,32 are now observed in infants too young to be fully vaccinated. Ways to reduce the disease burden in vulnerable infants include additional pertussis booster doses in childhood and adolescence, and pertussis vaccination of pregnant women and/or new parents/grandparents, and other adults in contact with newborn infants (the so-called “cocoon strategy”).33 There is growing interest in applying the cocoon strategy in Italy, although a pilot study suggests that good communication with parents and engagement of health care professionals is needed to reach high coverage.34,35

Acellular pertussis vaccines prevent severe pertussis disease in young children but recent evidence suggests that immunity wanes rapidly over time.36-39 Maintenance of strong immunization programs that achieve high coverage for primary and booster doses remains important for control of pertussis in countries where acellular vaccines are used. The availability of low antigen-content acellular pertussis vaccines (combined with diphtheria and tetanus) allows for regular boosting against pertussis throughout life. Because the optimal period between booster doses is not known, most countries with adult pertussis booster policies recommend a single life-time dose. However, booster doses administered every 10 y to coincide with recommendations for decennial diphtheria-tetanus boosters have been explored and would improve coverage and require no additional injections.40,41

**Hepatitis B**

The HBV component of DTPa-HBV-IPV/Hib is identical to Engerix™ B, for which efficacy and persistence of immune memory for at least 20 y after vaccination has been demonstrated in endemic regions.42,43 An anti-hepatitis B surface antigen (anti-HBs) antibody level of 10 mIU/ml is generally accepted as indicative of protection.44 In subjects vaccinated with DTPa-HBV-IPV/Hib at 3 and 5 mo of age, between 93.1% and 98.3% had anti-HBs antibodies ≥10 mIU/ml (Table 2). After the booster dose, the percentage of subjects with concentrations ≥10 mIU/ml was between 97.7% and 100%. In a key study conducted in Slovakia, the anti-HBs immune response following administration of DTPa-HBV-IPV/Hib at 3 and 5 mo of age was similar to monovalent HBV vaccine (96.4% ≥ 10 mIU/ml vs. 82.6%, respectively), with significantly higher antibody concentrations in the DTPa-HBV-IPV/Hib group.35 After the booster dose, 98.6% of DTPa-HBV-IPV/Hib.
Hib and HBV recipients had seroprotective anti-HBs antibody concentrations. Approximately 10 y after vaccination, administration of a booster dose of HBV vaccine demonstrated persisting anamnestic responses in more than 95% of subjects in both groups. Together these data indicate that administration of DTPa-HBV-IPV-Hib in the 3-5-11 schedule induced long lasting immune memory against HBV that was similar to that induced by monovalent HBV vaccines, for which protective efficacy has been demonstrated. The data are consistent with results observed in children who received three primary DTPa-HBV-IPV/Hib doses or three monovalent HBV doses, and in whom long-term antibody persistence and immune memory was demonstrated.

There have been two studies conducted in Italy that assessed long-term anti-HBs antibody persistence in children vaccinated with hexavalent vaccines. Hexavac™ (DTPa-HBV-IPV-Hib, Sanofi Pasteur), a fully liquid hexavalent vaccine, was suspended and withdrawn from the market in 2005 because of concerns about long-term protection afforded against hepatitis B. Both studies demonstrated that up to 5 y after vaccination, significantly higher percentages of DTPa-HBV-IPV/Hib-GSK-vaccinated children than DTPa-HBV-IPV-Hib-SP-vaccinated children had persisting anti-HBs levels ≥10 mIU/ml (83.2% vs. 38.4% at year 5). In children boosted with monovalent HBV vaccine, anamnestic responses were observed in the majority of children, regardless of vaccine group. The successor product to DTPa-HBV-IPV-Hib-SP was recently approved for use in the European Union.

**Polioymelitis**

Antibodies against poliovirus types 1, 2, and 3 were measured by a micro-neutralisation assay, with a 1:8 dilution (assay cut-off) considered seroprotective. In subjects vaccinated at 3-5-11 mo of age, the percentage with seroprotective antibodies for each poliovirus was between 94.3% and 100% after dose 2 and between 97.9% and 100% after dose 3 (Table 2). Poliovirus titers, but not seroprotection rates, were observed to be significantly lower (nearly half as low) after vaccination with DTPa-HBV-IPV-Hib-SP compared with DTPa-HBV-IPV/Hib. In Italy, a surveillance study confirmed that lower poliovirus titers (but not seroprotection rates) persisted in DTPa-HBV-IPV-Hib-SP vaccinated children compared with DTPa-HBV-IPV/Hib-vaccines 15 mo after dose 3.

Europe was declared free of poliovirus in 2002. Nevertheless, importation of wild virus strains from areas in which poliovirus continue to circulate remains a theoretical risk, and requires maintenance of immunity throughout life. A recent review of poliovirus seroepidemiology in Italy showed waning immunity with age, supporting the introduction of an adolescent poliovirus booster dose in Italy. Thus, induction of high poliovirus titers by hexavalent vaccines may be relevant in children, as they are expected to confer protection until the next IPV booster which is scheduled to be given at pre-school age.

**Hib**

Antibodies against the Hib polysaccharide, PRP, were measured by ELISA, with a cut-off of 0.15 μg/ml which is considered indicative of seroprotection. The percentage of subjects with seroprotective anti-PRP antibody concentrations was between 87.0% and 95.5% after dose 2, increasing to between 98.2% and 100% after the booster dose (Table 2).

The effectiveness of hexavalent vaccines, including DTPa-HBV-IPV/Hib, in preventing invasive Hib disease was investigated through a nation-wide surveillance in Germany over a 5-year follow-up period, the effectiveness of the Hib components of 2 hexavalent vaccines, one of which was DTPa-HBV-IPV/Hib, was 90.4% for a full 3-dose primary series and 100% for a full primary series plus booster dose (irrespective of the Hib vaccine used for priming).

Long-term effectiveness of Hib vaccine administered in DTPa-based combinations in the 3-5-11 schedule has also been demonstrated in Sweden, where the incidence between 2005 and 2008 was estimated to be 0.4 per 100 000 children 0–4 y of age. In Italy, the incidence of invasive *H. influenzae* disease began to decline when Hib vaccination was first introduced in 1998 (Fig. 1). Since 2006, the incidence of invasive *H. influenzae* disease has remained at, or less than, 0.12 per 100 000, with around half of the cases identified as non-typeable and very few as type b.

**Reactogenicity and Safety**

The reported reactogenicity profile of DTPa-HBV-IPV/Hib is similar to that of other inactivated vaccines, characterized by the...
Data in Pre-Term Infants

DTPa-HBV-IPV/Hib is specifically approved in the Summary of Product Characteristics for administration to premature infants. In clinical trials DTPa-HBV-IPV/Hib is immunogenic when administered in a 3-dose primary schedule to premature infants (<37 weeks of gestation), with the majority of subjects achieving antibody concentrations consistent with seroprotection after vaccination. Moreover, a booster dose of DTPa-HBV-IPV/Hib induced marked increases in antibody concentrations in toddlers who had been born prematurely, indicative of the development of immune memory and effective priming by DTPa-HBV-IPV/Hib.

In 2007 the Committee for Medicinal Products for Human Use reviewed cases of apnea in prematurely born infants following vaccination with different vaccines, and concluded that the occurrence of apnea following vaccination is increased in infants born very prematurely (<28 weeks of gestation) due to immaturity of the immune system. This was considered to be an issue for all vaccines administered in this population. The recommendation of the Committee to monitor very premature infants closely for up to 48–72 h after vaccination was included in the Summary of Product Characteristics for DTPa-HBV-IPV/Hib.

Co-Administration

There is extensive clinical trial experience with DTPa-HBV-IPV/Hib co-administered with other routinely recommended pediatric vaccines, including PCVs, rotavirus, meningococcal conjugate, measles, mumps, rubella, and varicella vaccines. In all studies the immune response was considered adequate. Specifically, clinical trials conducted in Italy showed that the immune response to DTPa-HBV-IPV/Hib antigens was similar when administered alone, or when co-administered with PCV7 or PCV13, with a clinically acceptable safety profile. Similarly, DTPa-HBV-IPV/Hib co-administered with a meningococcal serogroup C conjugate vaccine induced seroprotective antibody concentrations against all of the administered antigens, including meningococcal serogroup C, in the majority of subjects. Thus, in line with current recommendations concerning inactivated vaccines, DTPa-HBV-IPV/Hib can be co-administered with other live or inactivated vaccines without interference on the immune response.

Conclusion

DTPa-HBV-IPV/Hib has been licensed for use for 12 y and an extensive body of clinical trial and post-marketing experience attest to its safety and effectiveness in preventing diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Hib disease when administered alone, or co-administered with other vaccines in infants and young children, including infants born prematurely. A safety record over 12 y provides confidence to health care providers about the acceptable safety profile of DTPa-HBV-IPV/Hib.

In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use and nearly 15 million doses distributed. The use of DTPa-HBV-IPV/Hib in Italy has been associated with record levels of vaccine coverage, and with sustained disease control in vaccinated cohorts. Hexavalent vaccines

Adverse reaction values and adverse reaction. This is consistent with the established safety profiles of DTPa-HBV-IPV/Hib and PCV7, for which a higher occurrence of fever has been reported when infants receive both vaccines at the same vaccination visit.5 Adverse reaction values reported from Italy were higher to those of the rest of the world; however, in Italy vaccines undergo a national focused safety monitoring program where HCPs are requested to report all events, even those expected from SmPC such as fever.

More recently GlaxoSmithKline Vaccines performed an analysis to assess the occurrence of severe adverse events (fatalities, cardiorespiratory arrest, hypotonia/ hypotonic-hyporesponsive episode [HHE], and serious neurological disorders) occurring after vaccination with DTPa-HBV-IPV/Hib (co-administered with a PCV) during the period before and after the change from PCV7 to PCV13 in Italy (PCV7 reporting period 01-01-2008 until 31-04-2010; PCV13 reporting period 01-05-2012 until 18-07-2012). The reporting rate (number of reports per doses distributed) for fatalities in period when PCV7 co-administration was in use was 0.03 (95%CI 0.01; 0.14) compared with 0.11 (0.03; 0.29) when PCV13 was in use. The respective reporting rates for cardiorespiratory arrest were 0.31 (95% CI 0.16; 0.54) compared with 0.59 (0.36; 0.90), hypotonia/HHE 3.08 (2.55; 3.68), and 2.10 (1.65; 2.63) and for serious neurological events 4.05 (3.45; 4.74) and 4.56 (3.88; 5.31). The analysis did not show any major difference in the reporting rates of serious adverse events in Italy between the periods when DTPa-HBV-IPV/Hib was co-administered with PCV7 or PCV13.

Historical concerns about a potential temporal association between the occurrence of sudden unexpected death (SUD) and vaccination with hexavalent vaccines have been extensively investigated. In Germany, a population-based evaluation demonstrated a possible safety signal for DTPa-HBV-IPV-Hib-SP but failed to show an imbalance between observed and expected SUD cases for DTPa-HBV-IPV/Hib. A large case series conducted in Italy was unable to confirm the presence of a safety signal, but noted that the power of the study was low due to small number of SUD cases that occurred. In 2003 the European Medicines Agency concluded the absence of a cause-effect relationship and no change to the benefit-risk profile of the hexavalent vaccines then available.67
will continue to contribute to high vaccine coverage in Italy and across Europe.

Disclosure of Potential Conflicts of Interest

Marchetti F and Castro M are employees of GlaxoSmithKline group of companies and report ownership of stock options. During the last 5 years, Baldo V and Gabutti G have received grants from GlaxoSmithKline Biologics SA, Sanofi Pasteur MSD, Novartis, Crucell/Janssen, and Pfizer for taking part in advisory boards, expert meetings, being a speaker or an organizer of congresses/conferences, and acting as investigator in clinical trials. Franco E reports grants paid by Sanofi Pasteur MSD and Pfizer to her institution, and payments received from GlaxoSmithKline Biologics SA, Pfizer, Crucell and Sanofi Pasteur MSD for travel accommodations, meeting expenses; grants received by her institution from Novartis, Pfizer and Wyeth Lederle. Vitale F reports no conflict of interest.

Sources of Support

GlaxoSmithKline Biologics SA funded all costs associated with the development and the publishing of the present manuscript. The corresponding author had full access to the data and was responsible for submission of the publication.

Acknowledgments

The authors thank Daniel De Palmaena and Céline Verheust for safety analysis, Dr Joanne Wolter (independent) for preparing the first draft of the manuscript and medical writing support, and Jérémie Dedessus le Moutier (Business and Decision Life Sciences on behalf of GlaxoSmithKline Vaccines) for manuscript co-ordination and editorial assistance.

Trademark

Infanrix, Engerix, Hibercix and Menitrix are trademarks of the GlaxoSmithKline group of companies. Hexavac is a trademark of Sanofi Pasteur. NeisVac-C is a trademark of Baxter. Prevenar is a trademark of Pfizer.

References

1. Marshall GS, Happe LE, Lunacek OE, Seymansi MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496-500; PMID:17529866; http://dx.doi.org/10.1097/INF.0b013e31805d7317
2. Happe LE, Lunacek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on vaccination immunization in a state Medicaid population. Pediatr Infect Dis J 2009; 28:98-101; PMID:19480809; http://dx.doi.org/10.1097/INF.0b013e3181878047
3. Happe LE, Lunacek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care 2007; 13:506-12; PMID:17805364
4. Kalies H, Grote V, Verstraeten T, Hessl L, Schmitt H-J, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25:507-12; PMID:16752148; http://dx.doi.org/10.1097/00006454-199811000-00013
5. Infanrix hexa product information. 2011 Sep 14 [cited 2013 Feb 18]; Available from: http://www.ema.europa.eu/en/medicines/human/medicines/000296/human_med_000833.jsp&md=C0631a0ce58001d124
6. Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbrin. Expert Rev Vaccines 2007; 6:47-56; PMID:17280478; http://dx.doi.org/10.1586/evac.06.3
7. Bassinet L, Guiraud P, Maitre B, Housset B, Geunon P, Guissot N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect Immun 2000; 68:1934-41; PMID:10722585; http://dx.doi.org/10.1128/IAI.68.3.1934-1941.2000
8. Zepp F, Schmitt H-J, Cleerbrodt J, Verstraeten T, Schuereman L, Jacquet J-M. Review of 8 years of experience with Infanrix hexa (DTPaHBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009; 8:663-78; PMID:19485747; http://dx.doi.org/10.1586/evac.09.32
9. Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granström M, Blondeau C, Hoffenbach A. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17:1026-33; PMID:9849987; http://dx.doi.org/10.1097/00006454-199810000-00013
10. Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergård T, Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 1999; 18:884-91; PMID:10580202; http://dx.doi.org/10.1016/S0264-410X(99)00341-2
11. Marino MG, Franco E. [Immunization in the 3rd, 5th and 11th month of age: an Italian intuition]. Ig Sanita Pubblico 2008; 64:391-401; PMID:18936801
12. Sintesi anni 2000-2011 - Ministero della Salute. Vaccinazioni dell’età pediatria: copertura vaccinali* (per 100 abitanti) in Italia. 2012. Available from: http://www.salute.gov.it/imgc/_c_17_paginaA_r_e_881_listFile_isr/Name_11_file.pdf
13. Avdicová M, Prikazský V, Hudecková H, Schuereman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002; 161:581-7; PMID:12425482; http://dx.doi.org/10.1007/s00431-002-1079-5
14. Avdicová M, Crasta PD, Hardt K, Kovac M. Lasting immune memory against hepatitis B 10 years after the 2+1 primary vaccination schedule with DTPa-HBV-IPV/Hib or DTPa-IPV/Hib-HBV. 30th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID). Thessalonik, Greece. 2012.
15. Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age. Vaccine 2002; 20:2710-4; PMID:12354925; http://dx.doi.org/10.1016/j.vaccine.2002.02.024
16. Gabutti G, Zepp F, Schuereman L, Dentico P, Bamî F, Soncini R, Habermehl P, Knuf M, Covra P; Cooperative Italian Group for the Study of Combined Vaccines. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 2004; 36:585-92; PMID:15370707; http://dx.doi.org/10.1080/036554010017572
17. Kilpi TM, Silfverdal SA, Nilsson L, Sjöransen R, Belloni C, Desole M, Triban C, Storsæter J, Solia M, Jacquet JM. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin 2009; 5:18-25; PMID:18699013; http://dx.doi.org/10.4161/hv.5.1.6369
18. Verardi T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Bouriau D. A combined Haemophilus influenzae type b Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J 2013; 32:521-9; PMID:23190785; http://dx.doi.org/10.1097/INF.0b013e31827e22e3
19. Esposito S, Tansey S, Thompson A, Razmouz A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17:1017-26; PMID:20427630; http://dx.doi.org/10.1128/CVI.00620-10
20. Durando P, Crovari P, Ansaldui F, Sticchi L, Sticchi C, Turriolo V, Marenzi L, Giacchino R, Timitilli A, Carloni R, et al.; Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27:3459-62; PMID:19200823; http://dx.doi.org/10.1016/j.vaccine.2009.01.052
Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization immunosorbent assay in mice as a method for the estimation of tetanus toxoid in human sera. J Biol Stand 1983; 11:137-49; PMID:6435448; http://dx.doi.org/10.1186/s00212-1983-00009-8.

Camargo ME, Silveira L, Furuta JA, Oliveira EP, Gernek OA. Immunoenzymatic assay of anti-diphtheria toxoid antibodies in human serum. J Clin Microbiol 1984; 20:772-4; PMID:6588742.

Granström M, Thörén M, Blenow M, Tira M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987; 6:18-21; PMID:2883004; http://dx.doi.org/10.1007/BF02097184.

Karpinski KF, Hayward S, Triplomnas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987; 103:109-94; PMID:3668258; http://dx.doi.org/10.1016/0022-1759(87)90289-4.

Schmitt HJ, Schuind A, Knuf M, Beutel K, Schulte-Wissermann H, Gahr M, Schult R, Fokkens J, Rauh W, Bogaerts H, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria toxoids for primary vaccination in 22,505 infants. J Pediatr 1996; 129:695-701; PMID:8917236; http://dx.doi.org/10.1016/S0022-3476(96)70152-X.

Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Fokkens JU, Rauh W, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41; PMID:8531824; http://dx.doi.org/10.1001/jama.1996.03530250041024.

Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, et al.; Project Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-8; PMID:8587804; http://dx.doi.org/10.1056/NEJM199602283340401.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Italian Working Group. Sustained efficacy during the first years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:E81; PMID:11504665; http://dx.doi.org/10.1542/peds.108.5.e81.

Hallander HO, Gustafsson L. Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience. Expert Rev Vaccines 2009; 8:1303-7; PMID:19803750; http://dx.doi.org/10.1586/erv.09.88.

Nilsson L, Lepp T, von Segbeden K, Hallander H, Gustafsson L. Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance. Vaccine 2012; 30:2396-402; PMID:22494282; http://dx.doi.org/10.1016/j.vaccine.2011.10.089.

Gaburti G, Rota MC, Bonato B, Pirani R, Turlà G, Gabutti G. Immunogenicity of acellular pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32; PMID:22188029; http://dx.doi.org/10.1001/jama.2012.14999.

Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Balter M. Acellular pertussis vaccine combined with reduced diphtheria pertussis vaccine in children. N Engl J Med 2012; 367:1012-9; PMID:22790745; http://dx.doi.org/10.1056/NEJMoa1200850.

Tarrof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, et al.; Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52; PMID:23478868; http://dx.doi.org/10.1542/peds.2012-1928.

Quinn HE, McIntrye P. Pertussis vaccine effectiveness in Australia, 2011 [cited 21 June 2013]. Available from: http://www.ncbi.nlm.nih.gov/news/past-news-events/Day2011/HQ-Australia-PertussisWS-25_Aug11.pdf.

Booy R, Van der Meeren O, Ng S-P, Celzo F, Rota MC, Bonato B, Pirani R, Turlà G, Gabutti G. A central booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine 2010; 29:45-50; PMID:20794370; http://dx.doi.org/10.1016/j.vaccine.2010.05.025.

Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Jacquet JM. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2010; 15:656-62; PMID:20704493; http://dx.doi.org/10.1111/j.1365-2813.2010.01312.x.

Poovorawan Y, Chongsurivat W, Theaamboonlers A, Leroux-Coels G, Kuriyakosuke S, Lseysen M, Jacquet JM. Duration of protection against acute respiratory infection from hepatitis B vaccine in young adults. Vaccine Inf Dis J 2010; 51:656-62; PMID:20704493; http://dx.doi.org/10.1111/j.1365-2813.2010.01312.x.

Poovorawan Y, Chongsurivat W, Theaamboonlers A, Leroux-Coels G, Kuriyakosuke S, Lseysen M, Jacquet JM. Duration of protection against acute respiratory infection from hepatitis B vaccine in young adults. Vaccine Inf Dis J 2010; 51:656-62; PMID:20704493; http://dx.doi.org/10.1111/j.1365-2813.2010.01312.x.

Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Jacquet JM. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2010; 15:656-62; PMID:20704493; http://dx.doi.org/10.1111/j.1365-2813.2010.01312.x.

Poovorawan Y, Chongsurivat W, Theaamboonlers A, Leroux-Coels G, Kuriyakosuke S, Lseysen M, Jacquet JM. Duration of protection against acute respiratory infection from hepatitis B vaccine in young adults. Vaccine Inf Dis J 2010; 51:656-62; PMID:20704493; http://dx.doi.org/10.1111/j.1365-2813.2010.01312.x.
57. Patri AM. [From the goal of the global polio eradication to the recent epidemics: reflections on the present epidemiological situation and future perspectives]. Ann Ig 2010; 22:521-37; PMID:21245369

58. Kayhry H, Peltona H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100; PMID:6602191; http://dx.doi.org/10.1093/infdis/i67.6.1100

59. Kalies H, Grote V, Siedler A, Grondahl M, Schmitt J-H, van Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine 2008; 26:2545-52; PMID:18403609; http://dx.doi.org/10.1016/j.vaccine.2008.03.001

60. Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 2010; 118:878-87; PMID:20955461; http://dx.doi.org/10.1111/j.1600-0463.2010.02674.x

61. Cerquetti M. Haemophilus influenzae in epoca post-vaccinale. Rome: Workshop MIB; 2012. Available from: http://www.epicentro.iss.it/problemi/meningo/ http://www.epicentro.iss.it/problemi/meningo/pdf/ MIB_2012.pdf

62. Giufre M, Cardines R, Caporali MG, Accogli M, D’Ancona F, Cerquetti M. Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance. Vaccine 2011; 29:3857-62; PMID:21459175; http://dx.doi.org/10.1016/j.vaccine.2011.03.059

63. Kuhnert R, Schlaud M, Poethko-Müller C, Vennemann M, Fleming P, Blair PS, Mitchell E, Thompson J, Hecker H. Reanalyses of case-control studies examining the temporal association between sudden infant death syndrome and vaccination. Vaccine 2012; 30:2349-56; PMID:22289512; http://dx.doi.org/10.1016/j.vaccine.2012.01.043

64. von Kries R, Toschi AM, Strausburger K, Kundi M, Kalies H, Jennsilver K, Joch G, Rosenbauer J, Giani MIB. Sudden and unexpected deaths and vaccinations during the first two years of life in a case series study. PLoS One 2011; 6:e16363; PMID:21298113; http://dx.doi.org/10.1371/journal.pone.0016363

65. European Medicines Agency. EMEA update on diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus--Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005; 116:1292-8; PMID:16322149; http://dx.doi.org/10.1542/peds.2004-2336

66. Ométaça F, García-Sicilia J, García-Corbeira P, Bocera R, Romero A, Lopez G, Dal-Re R. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: before and after hexavalent vaccination. Vaccine 2011; 29:3857-62; PMID:21459175; http://dx.doi.org/10.1016/j.vaccine.2011.03.059

67. European Medicines Agency. EMEA update on diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio--Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004; 23:1109-15; PMID:15626947

68. Ométaça F, García-Sicilia J, García-Corbeira P, Bocera R, Romero A, Lopez G, Dal-Re R. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio--Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004; 23:1109-15; PMID:15626947

69. Tejedor JC, Moto M, Ruiz-Contraseras J, Castro J, Gómez-Campderá JA, Roca J, García-del-Río M, Alvarez M, Aránega J, Martín JM, Martín-Ancel A, Roca J, García-del-Río M. Study Group. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio--Haemophilus influenzae type b vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:713-20; PMID:16874171; http://dx.doi.org/10.1097/01. inf.0000227725.61495.c4

70. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papavangeli V, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21249417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009

71. Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, Beakers F, Descamps D, Willems P. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007; 166:857-64; PMID:17541639; http://dx.doi.org/10.1007/s00431-007-0565-2

72. National Center for Immunization and Respiratory Diseases. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64; PMID:21293327

73. Vesikari T, Omeñaca F, García-Sicilia J, Verduguer J, Van Esso D, Esporrín C, Molina V, Muro M, Marés J, Enrubia M, et al.; Spanish DTPa-HBV-IPV-097 Study Group. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio--Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004; 23:1109-15; PMID:15626947

74. Vesikari T, Omeñaca F, García-Sicilia J, Verduguer J, Van Esso D, Esporrín C, Molina V, Muro M, Marés J, Enrubia M, et al.; Spanish DTPa-HBV-IPV-097 Study Group. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio--Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004; 23:1109-15; PMID:15626947